Novartis Investigative Site

Buenos Aires, Buenos Aires F.D. C1431FWO

4 studies enrolling now · 10 studies all time

What they study most

Acute Heart Failure, Acute Myocardial Infarction, Carcinoma, Non-Small-Cell Lung, Coronary Artery Disease (CAD), Coronary Atherosclerosis, Glomerular Disease, Glomerulonephritis, Glomerulonephritis, IGA, Glomerulopathy, Healthy Volunteers, Pulmonary Arterial Hypertension, Immunoglobulin Disease, Kidney Diseases

Studies at this site

• A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis — Recruiting now
• A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B) — Recruiting now
• Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy. — Recruiting now
• A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) — Recruiting now
• Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1) — Completed
• Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI — Completed
• Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC — NO_LONGER_AVAILABLE
• Global Non-interventional Heart Failure Disease Registry — Stopped early
• Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients — Completed
• Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD) — Completed